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Objectives: To evaluate veno-occlusive disease of the liver
(VOD) and non-hepatic regimen related toxicity (RRT) in patients
receiving allogeneic stem cell transplantation (allo-SCT) after con-
ditioning with BUCY plus thiotepa, using an intravenous (IV)
formulation of busulfan. Patients and Methods: Twenty-six adult
patients (20 men and 6 women; median age 32 years) underwent
allo-SCT between 2002 and 2004 after conditioning with thiotepa
(10 mg/kg), CY (120 mg/kg) and IV BU (9.6 mg/kg). Fourteen
patients received anti-thymocyte globulin (ATG). Diagnoses were
acute leukemia or myelodysplastic syndrome (20 patients), chronic
myeloid leukemia (3 patients) and other diseases (3 patients). Ten
patients received grafts from HLA-identical siblings and 16 from
alternative donors (cord blood in 12 cases). GVHD prophylaxis
consisted of cyclosporin A (CsA) and prednisone in 16 cases, CsA
and methotrexate in 9 and CsA alone in 1. VOD and non-hepatic
RRT were assessed according to Baltimore and Bearman criteria,
respectively. Results were compared to 53 historical controls who
underwent allo-SCT between 1997 and 2004 using the same con-
ditioning regimen but giving oral BU (12 mg/kg) instead of IV BU.
Results: Four of 26 patients (15%) developed VOD which was
resolved before day 100 after transplant in all cases. Severe VOD
was not observed. Signiﬁcant increases (more than 2 fold) in AST
and total bilirubin levels were observed in 19 patients (73%). The
median maximum levels of AST and total bilirubin were 72 U/L
and 2 mg/dL, respectively. Sixteen patients (62%) developed non-
hepatic RRT that was greater than grade 1 in 13 cases (50%). The
VOD rate was not signiﬁcantly different when comparing patients
receiving IV BU and oral BU (15% vs. 6%; P  0.2). However,
non-hepatic RRT was more frequent among patients receiving oral
BU (92% vs. 61%; P .002), with a higher toxicity rate of grade 2 or
more (76% vs. 50%; P  0.02). No differences were found between
the two groups regarding the underlying disease, type of transplant,
age of patients and use of ATG. MTX was more commonly used in
patients receiving IV BU (35% vs. 15%; P  0.05). Conclusions:
The use of IV BU seems to reduce non-hepatic toxicity after condi-
tioning with BUCY plus thiotepa for allo-SCT.
97
LESS TRANSPLANT-RELATED MORTALITY WITH VARIABLE INTENSITY
CONDITIONING THAN NON-MYELOABLATIVE CONDITIONING IN UNRE-
LATED AND RELATED ADULT ALLOGENEIC TRANSPLANT RECIPIENTS
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sissippi Medical Center, Jackson, MS.
For the past four years, our adult allogeneic transplant program
has employed two alternative approaches to standard recipient
conditioning, the use of non-myeloablative “mini” conditioning
and variable intensity conditioning. We now report a retrospective
comparison of relapse, day 100 and one-year survival, engraft-
ment and grades I-II and III-IV acute GVHD in unrelated as well
as related recipients in these two preparative regimen groups.
Patients with a variety of malignancies were not randomized to
receive either non-myeloablative (Group 1) or variable intensity
(Group 2) conditioning. Twenty patients with a median age of 49
(range 27–64, Group 1) and 18 patients also with a median age of
49 (range 24–58, Group 2) received either marrow or peripheral
blood stem cells, usually with a 6/6 match grade. One recipient in
Group 2 received a cord blood transplant (4/6 match). Group 1
regimen consisted of four protocols: ﬂudarabine 30 mg/m2  3 d
and TBI 200 cGY; ﬂudarabine  6 d, busulfan 4 mg/kg  2 d and
ATG 40 mg/kg 4 d; ﬂudarabine 5 d and cyclophosphamide 60
mg/kg  2 d; ﬂudarabine, cyclophosphamide, ATG. Group 2
regimen consisted of Campath 20 mg/d either 5 or 3 days, ﬂudara-
bine  5 d and melphalan 140 mg/m2  1 d. GVHD prophylaxis
was the same in both groups (standard dose cyclosporine or ta-
crolimus and MMF.) All patients received an adequate CD34 cell
dose and none of the products was manipulated. Relapse rate was
16% in Group 1 and 33% in Group 2. Day 100 survival and
one-year survival were 55% and 25%, respectively, in Group 1 vs
69% and 42% in Group 2. Only one patient in Group 2 had acute
GVHD, grades I-II; none had grades III-IV. However, in Group 1,
6 patients had grades I-II and 7 had grades III-IV (39%). Graft
failure occurred in four patients in Group 1, while no patients in
Group 2 experienced it. We conclude, ﬁrst, that in our program
the application of variable intensity conditioning has been quite
successful in unrelated transplant recipients, as well as in related.
Second, signiﬁcant treatment related mortality in the form of graft
failure and acute GVHD occurred less frequently in recipients who
received this conditioning than in those receiving non-myeloabla-
tive conditioning. This regimen requires some modiﬁcation to
enhance its tumoricidal properties; however, its treatment-related
toxicity is minimal and allows us to offer this therapy to patients
with co-morbid conditions and older age.
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REPLACEMENT DONOR PROGRAM: MORE THAN PROTECTING STEM
CELL DONORS FROM MULTIPLE DONATIONS FOR DIFFERENT PA-
TIENTS
Baier, D.M.; Gawellek, A.; Rutt, C. DKMS Deutsche Knochenmark-
spenderdatei gGmbH, Tuebingen, Germany.
Goal of DKMS’ Replacement Donor Program is to provide an
alternative donor for search centers in case that a donor has
completed a stem cell donation and is reserved for potential further
donations for the same patient for 2 years. First intention is to
provide a donor as long as possible for “his” patient afterwards the
2 year suspension. This would enable us to provide second or
further stem cell donations if required for the one patient. Second
intention is to protect the donor from requests for multiple pa-
tients. It could be observed several times that post-donation donors
were of increased interest for search centers and were requested for
conﬁrmatory typing (CT) several times. Providing alternative do-
nors would take off the burden from a single donor. Third inten-
tion is to ﬁll up the gap in HLA-phenotypes when a donor is
suspended from further donations for 2 years after donation and to
increase the number of high resolution typed donors at DKMS.
We think that donor centers like the DKMS have the responsibil-
ity to protect their donors from excessive demand by search cen-
ters. Forth intention is to provide an alternative donor for donors
in actual workups in case that the donor in workup is unavailable
for unpredictable reasons. As the search for the Replacement Do-
nor starts with initiation of the workup it is very important that the
full HLA-phenotype of the patient is available as early as possible.
We perform up to 100 DRB1* intermediate resolution or up to 5
DRB*/DQB1* high resolution typings with IDMs (CMV) on our
own behalf for each donor at initiation of workup per own search
to ﬁnd a Replacement Donor. Own searches are repeated two
times. Until October 2004, over 87000 HLA-DRB1* typings on
intermediate and 8600 high resolution typings of HLA-DRB* and
HLA-DQB1* were performed to provide Replacement Donors for
more than 3200 donors. Replacement Donors could be found for
994 donors to date. We could not only ﬁnd Replacement Donors
but also improved the quality of our database. This is shown by the
fact that over 3900 further requests (high resolution typing or
conﬁrmatory typing) and 340 workups could be observed out of the
over 95000 “prospective” typings. Only a few (7) stem cell donors
donated again for another patient since start of the project. In 5
cases a Replacement Donor could replace an unavailable donor
while the workup was still in process. (DKMS performed over 3900
donations since start of this project in 2001.)
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